0001493152-25-001782.txt : 20250110 0001493152-25-001782.hdr.sgml : 20250110 20250110171528 ACCESSION NUMBER: 0001493152-25-001782 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250106 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250110 DATE AS OF CHANGE: 20250110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Matinas BioPharma Holdings, Inc. CENTRAL INDEX KEY: 0001582554 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 463011414 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38022 FILM NUMBER: 25523915 BUSINESS ADDRESS: STREET 1: 1545 ROUTE 206 SOUTH STREET 2: SUITE 302 CITY: BEDMINSTER STATE: NJ ZIP: 07921 BUSINESS PHONE: 908-484-8805 MAIL ADDRESS: STREET 1: 1545 ROUTE 206 SOUTH STREET 2: SUITE 302 CITY: BEDMINSTER STATE: NJ ZIP: 07921 8-K 1 form8-k.htm
false 0001582554 0001582554 2025-01-06 2025-01-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 6, 2025

 

 

 

MATINAS BIOPHARMA HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38022   46-3011414

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

ID Number)

 

1545 Route 206 South, Suite 302

Bedminster, New Jersey

  07921
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (908) 484-8805

 

Not Applicable

(Former name or former address, if changed since last report.)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol   Name of Each Exchange on Which Registered
Common Stock   MTNB   NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

On January 6, 2025, Matinas BioPharma Holdings, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the NYSE American LLC (“NYSE American”) stating that the Company failed to hold an annual meeting of stockholders during its fiscal year ended December 31, 2024, as required by Section 704 of the NYSE American Company Guide (the “Company Guide”). A copy of the press release that discusses this matter is furnished as Exhibit 99.1 hereto and incorporated herein by reference.

 

The Notice has no immediate impact on the listing of the Company’s common stock, which will continue to be listed and traded on the NYSE American during the applicable cure period, but will be assigned a “.BC” indicator by the NYSE to indicate that the Company is below compliance. The “.BC” indicator will be removed at such time as the Company is deemed compliant with the NYSE’s continued listing standards.

 

The Company intends to hold its annual meeting no later than December 31, 2025 in order to regain compliance under the Company Guide.

 

Forward- Looking Statements

 

This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to compliance with NYSE American listing standards. All statements other than statements of historical fact are statements that could be forward-looking statements.

 

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expects,” “anticipates,” “intends,” “plans,” “could,” “believes,” “estimates” and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, the sale of MAT 2203, and the evaluation of other alternatives for the Company, including a winddown or dissolution of the Company; and the other factors listed under “Risk Factors” in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. The Company’s product candidates are all in a development stage and are not available for sale or use.

 

Item 9.01 Financial Statements and Exhibits.

 

Exhibit No.   Description
99.1   Press Release, dated January 10, 2025
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

-2-
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MATINAS BIOPHARMA HOLDINGS, INC.
     
Dated: January 10, 2025 By: /s/ Jerome D. Jabbour
  Name: Jerome D. Jabbour
  Title: Chief Executive Officer

 

-3-

 

EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

Matinas BioPharma Receives NYSE Noncompliance Notice

 

BEDMINSTER, N.J. (January 10, 2025)Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) announces that on January 6, 2025, it received a NYSE American LLC notice indicating that the Company has fallen below certain NYSE American continued listing standards because it failed to hold its annual meeting of stockholders for the fiscal year ending on December 31, 2024, as set forth in Section 704 of the NYSE American Company Guide.

 

The Company intends to hold its annual meeting no later than December 31, 2025 in order to regain compliance under the NYSE American Company Guide.

 

About Matinas BioPharma

 

Matinas BioPharma is a biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology.

 

For more information, please visit www.matinasbiopharma.com.

 

Forward-looking Statements

 

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to compliance with NYSE American listing requirements, and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as “expects,” “anticipates,” “intends,” “plans,” “could,” “believes,” “estimates” and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, the sale of MAT 2203, and the evaluation of other alternatives for the Company, including a winddown or dissolution of the Company; and the other factors listed under “Risk Factors” in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma’s product candidates are all in a development stage and are not available for sale or use.

 

Investor Contact

 

Jerome Jabbour

Chief Executive Officer

(908) 484-8805

operations@matinasbiopharma.com

 

# # #

 

 

 

GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 mtnb-20250106.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 mtnb-20250106_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 mtnb-20250106_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.4
Cover
Jan. 06, 2025
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 06, 2025
Entity File Number 001-38022
Entity Registrant Name MATINAS BIOPHARMA HOLDINGS, INC.
Entity Central Index Key 0001582554
Entity Tax Identification Number 46-3011414
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1545 Route 206 South
Entity Address, Address Line Two Suite 302
Entity Address, City or Town Bedminster
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07921
City Area Code (908)
Local Phone Number 484-8805
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol MTNB
Security Exchange Name NYSEAMER
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.4 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://matinasbiopharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm mtnb-20250106.xsd mtnb-20250106_lab.xml mtnb-20250106_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "MTNB", "nsuri": "http://matinasbiopharma.com/20250106", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "mtnb-20250106.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "labelLink": { "local": [ "mtnb-20250106_lab.xml" ] }, "presentationLink": { "local": [ "mtnb-20250106_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 23 }, "report": { "R1": { "role": "http://matinasbiopharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2025-01-06", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2025-01-06", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001493152-25-001782-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-25-001782-xbrl.zip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end XML 17 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001582554 2025-01-06 2025-01-06 iso4217:USD shares iso4217:USD shares false 0001582554 8-K 2025-01-06 MATINAS BIOPHARMA HOLDINGS, INC. DE 001-38022 46-3011414 1545 Route 206 South Suite 302 Bedminster NJ 07921 (908) 484-8805 false false false false Common Stock MTNB NYSEAMER false